Pleural Effusions

Another interesting study entitled "Phase studies of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small cell lung cancer" by LL Herscher, SM Hahn, Kroog G, H Pass, B Temeck, Goldspiel B, J Cook, JB Mitchell and J Liebmann

Another interesting study entitled "Phase studies of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small cell lung cancer" by LL Herscher, SM Hahn, Kroog G, H Pass, B Temeck, Goldspiel B, J Cook, JB Mitchell and J Liebmann

Another interesting study entitled "Phase studies of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small cell lung cancer" by LL Herscher, SM Hahn, Kroog G, H Pass, B Temeck, Goldspiel B, J Cook, JB Mitchell and J Liebmann

Another interesting study entitled "Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma" J Mezger, R and W Lamerz Permanetter - Department of Internal Medicine III, Klinikum Grosshadern, Munich, Federal Republic of Germany. . Journal of Thoracic and Cardiovascular Surgery, Vol 100, 860-866 Here is an excerpt, "histologic and cytologic distinction of malignant mesothelioma cancer metastases in the pleura or peritoneum is often problematic because of immunological method. Increasingly used as diagnostic adjuncts. U this review summarizes 40 studies on carcinoembryonic antigen expression in mesotheliomas and lung and other cancers, including the pleura or peritoneum. carcinoembryonic antigen was identified immunohistochemically in 11% of mesotheliomas and 84% of cancers examined and immunocytochemically (in serous effusion) in 4% and 58%, respectively . in serum and pleural or ascitic fluid, significantly elevated levels of carcinoembryonic antigen are often associated with (lung) cancer, but rarely with mesotheliomas. So, together with the identification of antigens in serum, pleural fluid, or ascitic fluid, immunohistochemical and immunocytochemical techniques for detecting carcinoembryonic antigen to provide valuable help to distinguish malignant mesothelioma from metastatic carcinoma ."

We all owe debt of gratitude to these fine researchers. If you find any of these statements interesting, please read the study in its entirety.

Seminars in Oncology - Volume 29, Number 1, pages 62-69 (February 2002) Paul Baas

Seminars in Oncology - Volume 29, Number 1, pages 62-69 (February 2002) Paul Baas...

Another interesting study entitled "Production of intrapleural interleukin-6 in mesothelioma and its modulation by γ-interferon treatment" by Gianpaolo Monti, Marie-Claude Jaurand, Isabelle Monnet, Pascale Chretien, Laure Saint-Etienne, Lin Zeng . Alain Portier, Philippe Devillier, Pierre Galanaud, Jean Bignon, and Dominique Emilie - Cancer Res August 15, 1994 54, 4419 Here is an excerpt: "Abstract - In vivo production of monokines was analyzed in 17 human malignant pleural mesotheliomas. High concentrations of interleukin-6 (IL-6) were detected in the pleural effusion, in contrast to the low levels of IL-1β and tumor necrosis factor α. This production originated from the malignant cells, as shown by immunochemical analysis of pleural cells and the production of IL-6 from the mesothelial cell lines. intrapleural administration of recombinant human interferon γ-six patients has led to a significant reduction in intrapleural IL-6 concentrations in all cases. This treatment was associated with in situ activation of macrophages and cytotoxic T-lymphocytes, as evidenced by increased intrapleural neopterin and soluble CD8 concentration. in vitro γ-interferon had no effect on the production of IL-6 by mesothelial cell lines, but reduced growth of 3 of 6 mesothelioma cell lines. These results suggest that systemic manifestations of malignant mesothelioma, including fever, cachexia, and thrombocytosis May apply the production of IL-6 by malignant cells, and that the local infusion of γ-interferon can reduce production by stimulating antitumoral immunity and / or directly reduces the proliferation of malignant cells. "

Another interesting study called "long-term survival in peritoneal mesothelioma and the role of radiotherapy in combined modality treatment" by Gilbert S. Lederman MD, Abram Recht Dr. Terence Herman Dr. Robert Defective Dr. Joseph Corson MD, Karen H. antman MD - Cancer Volume 59, Issue 11, 1882 to 1886 pages, 1 June 1987 Here is an excerpt:. "Summary - Ten patients with peritoneal mesothelioma were treated at the Joint Center for radiation therapy between 1968 and 1985. Six out of ten patients remained free of disease at 19 + to 78 + months after diagnosis. Six patients received sequential surgical debulking, combination chemotherapy, and whole abdominal irradiation. four patients not treated with this multimodality approach died with the disease. this approach could have an impact on the natural course of peritoneal mesothelioma, and warrants further study ."

Another interesting study entitled "Somatic genetic alterations in human malignant mesothelioma (Review)." Lee WC, Testa JR. - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA Int J Oncol .. 1999th January, 14 (1) :181-8 Here's an excerpt: "Summary - review of cytogenetic and molecular genetic findings in human malignant mesotheliomas (MMS) shows a composite profile of somatic genetic changes characteristic of MMS. MultiStep implies a process of tumorigenesis of this malignancy. Specifically , the emergence of multiple, recurrent cytogenetic deletions in MMS suggests that the loss and / or inactivation of tumor suppressor genes (TSGs) are critical for the development and progression of these tumors. Karyotypic and comparative genomic hybridization analysis of MMS showed frequent deletion of specific regions within chromosome arms 1p, 3P, 6Q, 9p, 15q and 22q, and subsequent loss of heterozygosity (LOH) studies have documented high frequencies of allele loss from each of these chromosomal sites. Positional candidate gene approaches have identified TSGs within two of these regions, ie, p16 / CDKN2A at 9p21 and NF2 at 22q12, which are often changed to MMS. homozygous deletion seems to be the main mechanism affecting p16/CDKN2A, while inactivating mutations in combination with loss of alleles occur in NF2 place. high-density LOH analysis of the stress minimum region of deletion in 1P, 3P, 6Q and 15q and is expected to facilitate efforts to identify national TSGs in these places that contribute to the pathogenesis of MMS. "

Mesothelioma is a malignant growth of cells in the mesothelium, a thin membrane that covers the internal organs of the body. This mesothelium lining covers the pleural, peritoneal and pericardial cavities. The pleura is the membrane covering the lungs and this is usually where the mesothelioma cancer also occurs, known as pleural mesothelioma. Peritoneum, the protective covering that lines the abdominal cavity can develop malignant tumors and cause.

Mesothelioma is one of the rarest in the world of cancer that is caused only by exposure to asbestos. His presentation can be as direct or indirect inhalation of asbestos exposure in which they inhaled asbestos particles from clothing, hair, equipment or other items that had previously been exposed to asbestos.

Causes Mesothelioma
Asbestos is a naturally occurring fibrous mineral that is mined in various parts of the world because of its usefulness in a wide variety of industries. However, it is a deadly carcinogen too and mojor and asbestosis.

Asbestos fibers are known to cause cancer of the mesothelium. Asbestos is a fibrous form of several minerals and hydrous silicates of magnesium found in the ground. There are 3 types of asbestos, blue, and one brown. Of all these 3 species, also called blue amphibole, long and thin in structure is more carcinogenic than white or chrysolite asbestos or the brown one known as amosite.

Another interesting study titled "Pleurectomy / decortication in the setting of multimodality treatment of diffuse malignant pleural mesothelioma." Do Rusch VW.
Memorial Sloan-Kettering Cancer Center, Department of Surgery and Cornell University Medical College, New York, NY 10021st Semin Thorac Cardiovasc Surg. . October 1997, 9 (4) :367-72 Here's an excerpt: "Abstract - Pleurectomy / decortication is frequently performed operation for patients with diffuse malignant pleural mesothelioma (DMPM) has a low surgical mortality (manje. than 5%), but is associated with significant risk of local recurrence. to date, intensive adjuvant chemotherapy or radiation is not reduced this risk. Despite these disappointing results, pleurectomy / decortication May still be the best treatment option for some patients, particularly those with early disease whose condition excludes pneumonectomy. role of pleurectomy / decortication combined with newer treatment strategies such as neoadjuvant therapy or gene therapy warrants investigation ."

Another interesting study titled "The presence of simian virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor." Do Cacciotti P, Strizzi L, Vianale G, L Iaccheri, Libener R, Porta C, Tognoni M, Gaudino G, Mutti L - Am J Respir Cell Mol Biol. 2002 February, 26 (2) :189-93.
Here is an excerpt: "Abstract - The aim of this study was to assess whether the presence of simian virus-40 (SV40) is associated with an increased release of vascular endothelial growth factor (VEGF) in human malignant mesothelioma (MM) cells Mi. Studied nine cell lines derived from pleural effusion (PE) in patients with MM, and three different cultures of normal human mesothelial cells (NHMC) derived from pleural fluid of patients with congestive heart failure. NHMC were transfected with full length SV40 (NHMC-FL) or large T antigen (Tag NHMC ) DNA. high levels of VEGF were detected in the conditioned media, each of the two MM cells that tested positive for SV40 by PCR amplification and Southern hybridization and dried Tag transcript by reverse transcription-polymerase chain reaction (RT-PCR) and immunoprecipitation. we also found that NHMC-FL released high amounts of VEGF. Conditioned medium from SV40-positive MM cells and from FL-NHMC increased proliferation of human umbilical vein cells (HUVEC) and this effect was partially reversed the addition of specific antibodies against VEGF blocker. These results provide the first evidence that SV40 can cause VEGF release in SV40-positive MM cells and that the whole viral genome is required for this effect ."

We all owe debt of gratitude to these fine researchers for their work. If you find any of these statements of support, read the study in its entirety.

Every year in the United States, about 3000 people will get a rare form of cancer called mesothelioma. It is usually attributed to asbestos exposure sometime in the distant past, this sort of cancer can take decades to mature into full-fledged cancer.

Prognosis for mesothelioma patients are usually pretty useless. Your doctor will likely perform a medical history and examination done to look for signs of mesothelioma, such as pleural effusion, ascites or pericardial efflusion. Since it is so rare, a general overview is largely not performed. Tests are frequently conducted for those who are exhibiting symptoms or those at risk.

This is because fees statement issued from asbestos suppliers. In addition, statements were also against the asbestos companies that are exposed to their staff on this dangerous substance without issuing a good basic security advice and security. These links include health groups and doctors who definitely could be an aid in acquiring a victim or a buyer fully understand the circumstances much better. Of course, this does not automatically respect that having a lawyer specializing in mesothelioma litigation will immediately win the case. It is also critical to think that you must give your lawyer enough time so that he can get ready to firmly state that will be presented in court. In addition, treatment for this killer is, however, terribly controversial that allow a variety of support (palliative) treatment by itself to an aggressive multi-dimensional treatment. Calculation, it is possible scientific tests within just a carefully organized the patients are important to see what ways the management can get the best survival benefit.

At this time, chest tube drainage through a tube located inside the chest and pleurodesis ", a process that leads to all-lining around the lungs to stay with each other and prevents the growth of liquid", is thought to be the most normal method of convenience treatment for the treatment of malignant pleural mesothelioma. These checks, along with a great, great translation review showed that many movements have real likely to strengthen the chances of patients at the time of raising the frequency.

will fight for you and get you the money you deserve if you are infected with mesothelioma

mesothelioma and asbestos related cases, some of the most difficult cases to understand and litigate.

mesothelioma can develop 25-40 years after they've been in the asbestos fibers and may happen even if they were exposed only for 1 or 3 years or less. Some people with mesothelioma have no history of exposure to asbestos.

, significant chest pain, and weight loss. one aspect of this deadly disease that will expand the production of tumors in other parts of the body, although in some cases the tumors were confined to the chest. Accumulation of fluid between two layers of pleural membranes (pleural effusion) often contributes to the shortness of breath and chest pain

Another interesting study called "effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma." Arch Pathol Lab Med. 1990th August, 114 (8) :845-51 Sherman ME, Mark EJ - James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston Here is an excerpt: "Abstract -
We reviewed cytologic findings in pleural effusions of 36 patients with epithelioid or biphasic diffuse malignant mesothelioma of the pleura developed between 1978 and 1988. Malignant neoplasms were diagnosed in 26 (72%) of 36 pacijenata.Specifična diagnosis of mesothelioma was made or suspected in 64% (23/36 patients). Mesothelioma is a favorite for more than adenocarcinoma in 81% (29/36) of patients with positive fluid cytology findings. Contribution effusion cytology to the diagnosis and treatment of patients was evaluated. These data suggested that the diagnosis has contributed useful information in most patients with malignant epithelioid and biphasic pleural mesotheliomas ."

We reviewed cytologic findings in pleural effusions of 36 patients with epithelioid or biphasic diffuse malignant mesothelioma of the pleura developed between 1978 and 1988. Malignant neoplasms were diagnosed in 26 (72%) of 36 pacijenata.Specifična diagnosis of mesothelioma was made or suspected in 64% (23/36 patients). Mesothelioma is a favorite for more than adenocarcinoma in 81% (29/36) of patients with positive fluid cytology findings. Contribution effusion cytology to the diagnosis and treatment of patients was evaluated. These data suggested that the diagnosis has contributed useful information in most patients with malignant epithelioid and biphasic pleural mesotheliomas ."

Malignant mesothelioma is a rare cancer of the lining of the lungs (pleural mesothelioma) or the lining of the abdomen (peritoneal mesothelioma). The only known cause of mesothelioma in the USA by exposure to asbestos. Mesothelioma has a long latency period, time between first exposure to asbestos and diagnosis of disease. In rare cases the latency period is as short as 10-15 years after the first exposure to asbestos, however, mesothelioma usually occurs between 20 and 40 or more years after the first exposure of an individual. Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions.

Benign mesothelioma is a non-cancerous tumor of the pleura (the lining of the lungs and chest cavity). Nonmalignant mesothelioma is usually a localized tumor that affects men more frequently than žene.Tumor can grow to large size and compress the lungs, which then causes the following symptoms: chronic cough, shortness of breath, chest pain, weight loss and cachexia, swelling and pain abdomen due to ascites (fluid accumulation in the abdominal cavity).

Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia and fever. If the cancer has spread beyond the mesothelium to other parts of the body, symptoms may include pain, difficulty swallowing, or swelling of the neck or face. These symptoms may be caused by mesothelioma or other, less serious conditions.

Approximately half of mesothelioma patients asymptomatic (no symptoms of disease). During the physical examination, health care services can be seen clubbed appearance of the fingers in a patient, which is an indicator of exposure / disease.The health professional can run tests that identify mesothelioma. These tests include chest x-ray, CT thorax and / or lung biopsy and open.

Surgery is usually needed in general for a solitary tumor (if found), however, according to current statistics, the outcome of the surgery is expected to be good with prompt treatment. One of the most common complication, although the pleural effusion (fluid escaping into the membranes around the lungs), which can be very serious.

Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or they were exposed to asbestos dust and fibers in other ways, such as washing clothes of a family member who worked with asbestos, or home renovation using asbestos cement products.

The second study is called "fat cell membranes revealed immunocytochemical staining: a trace of a diagnosis of mesothelioma," Anthony Y. Leong MD, MB, FRCP, FRCPath, FCAP, Richard Parkinson, James Milios HT. - Diagnostic Cytopathology - Volume 6, Number 1, pages 9-13, January 1990 Here's an excerpt: "
Summary - a difference of malignant mesothelioma from metastatic adenocarcinoma in pleural effusions and biopsies are often diagnostic problem. Immunocytochemical staining of 13 malignant mesotheliomas, eight of primary adenocarcinoma of the lung, five metastatic adenocarcinoma of the lung, and 20 primary adenocarcinomas of the extrapulmonary sites with a monoclonal antibody to epithelial membrane antigen (EMA) revealed a 'thick' of the cell membrane in all cases of mesothelioma. This characteristic pattern of staining was seen on the periphery of cell clusters and circumferentially around individual cells in cytologic preparations, cell blocks and tissue sections. Intracel-Mar and the intercellular acini are listed by the anti-EMA, and intraluminal long microvillous projections showed. Weak cytoplasmic staining is only rarely seen in mesothelioma cells. This membranous staining pattern was not observed in adenocarcinomas, which shows strong and diffuse cytoplasmic bojenje.Imunocitokemijska demonstration of dense and spiky membrane circumferentially disposed around individual cells corresponding to a distorted microvilli, a diagnostic clue in identifying malignant mesothelioma ."

Summary - a difference of malignant mesothelioma from metastatic adenocarcinoma in pleural effusions and biopsies are often diagnostic problem. Immunocytochemical staining of 13 malignant mesotheliomas, eight of primary adenocarcinoma of the lung, five metastatic adenocarcinoma of the lung, and 20 primary adenocarcinomas of the extrapulmonary sites with a monoclonal antibody to epithelial membrane antigen (EMA) revealed a 'thick' of the cell membrane in all cases of mesothelioma. This characteristic pattern of staining was seen on the periphery of cell clusters and circumferentially around individual cells in cytologic preparations, cell blocks and tissue sections. Intracel-Mar and the intercellular acini are listed by the anti-EMA, and intraluminal long microvillous projections showed. Weak cytoplasmic staining is only rarely seen in mesothelioma cells. This membranous staining pattern was not observed in adenocarcinomas, which shows strong and diffuse cytoplasmic bojenje.Imunocitokemijska demonstration of dense and spiky membrane circumferentially disposed around individual cells corresponding to a distorted microvilli, a diagnostic clue in identifying malignant mesothelioma ."